Recombinant factor VIII for hemophilia treatment

Hemophilia is an X-linked recessive hereditary disorder. This geneticdisorder results in reduced and delayed production of thrombin, so adisturbance happens in Clotting. Therefore, reduced activation of factor VIIIin these patients leads to Prolonged bleeding or an abnormal delay in therecovery of wounds. Treatment of Hemophilia is possible with injectingConcentrate of factor VIII according to the severity of the patient's disease.The first trials were done with detached factor VIII from normal individual'sserum, but this treatment had its Disadvantages like Immune system responseagainst the Injected contents or Viral disease transmission (i.e. hepatitis, aidsor ...). therefore, scientists began to use recombinant factor VIII for treatment.Recombinant factors are mainly produced in mammal's expression systems,for instance, human cells or Chinese hamster ovary's cells. At first, a specialcell line of human cells was used for the production of factors, namedHEK۲۹۳ cells that even now companies are using this cell line for theirCommercial production because the mentioned cell line has advantages likebeing able to live in suspensions without serum, attachment capability,producing proteins with high efficiency. The Process of producingrecombinant products like factor VIII includes using recombinant cDNA andinjecting it to target cells and placing it in Laboratory conditions, the onset ofproduction, isolation of product with Ion exchange chromatography, andfinally Lyophilization. manufactured recombinant factor VIII contains an ۸۰Kilo Dalton protein and some other peptides. The average degradation halflifeis more than the half-life of plasma's factor VIII. In conclusion,considering the advantages and safety of recombinant factor VIII (Comparedwith plasma ones), production and use of it are more common.

کلیدواژه ها:

factor VIII ، hemophilia ، Recombinant ، treatment ، HEK۲۹۳